Active	Status	Sponsor type	Region	Phase	Filter
16 Active 14 Inactive 30 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vey, Norbert
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML	Recruiting	3	322	Europe, Canada, US	Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF	Arog Pharmaceuticals, Inc.	Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations	10/24	10/24
AVENHIR, NCT05768711: Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia	Recruiting	2	44	Europe	Venetoclax, ABT-199	Groupe Francophone des Myelodysplasies, AbbVie	Chronic Myeloid Leukemia	02/26	10/28
EVICTION, NCT04243499 / 2019-003847-31: First-in-Human Study of ICT01 in Patients With Advanced Cancer Data from EVICTION study in combination with Keytruda for solid tumor at ESMO 2022 Sep 2022 - Sep 2022: Data from EVICTION study in combination with Keytruda for solid tumor at ESMO 2022	Recruiting	1/2	150	Europe, US	IV ICT01	ImCheck Therapeutics, ImCheck Therapeutics, Inc.	Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer	06/25	12/25
NCT05211570 / 2020-005122-28: AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia	Recruiting	1/2	78	Europe, US	AB8939, Azacitidine	AB Science, AB Science	Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia	12/24	12/24
NCT05782127: Oral Azacitidine Combined with Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes	Recruiting	1/2	36	Europe	Onureg + Venetoclax, CC-486 + ABT-199	Groupe Francophone des Myelodysplasies, Bristol-Myers Squibb, AbbVie	Untreated Myelodysplastic Syndrome	11/25	11/28
NCT05181735: Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA	Recruiting	1/2	150	Europe	Luspatercept Injection [Reblozyl], ACE-536, Eprex, Epoietin alfa	Groupe Francophone des Myelodysplasies, Celgene	MDS, Myelodysplastic Syndromes	05/27	11/27
Castillo, Laura
No trials found